Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cybrexa Therapeutics
Exelixis Looks To Early-Stage Option Rights As Low-Risk Pipeline Expansion Play
The maker of Cabometyx wants to expand its oncology pipeline via deal-making but is wary of the high attrition rate in cancer. Option deals with Cybrexa and Sairopa may avoid some of that risk.
- Drug Delivery
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.